Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets to support infrastructure ...

Emergent BioSolutions (EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread ...

Emergent BioSolutions (EBS) and Rocketvax announced entry into an agreement for Emergent’s strategic financial investment into Swiss Rockets, ...

As part of the investment, Emergent would lead U.S. manufacturing and commercialization efforts for four of Rocketvax’s ...

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...

Q4 2024 Earnings Call Transcript March 3, 2025 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $0.05, ...

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving ...

USA-based Emergent BioSolutions (NYSE: EBS) and Swiss vaccines firm Rocketvax have announced an agreement. One part of the ...

As Emergent BioSolutions continues to pawn off manufacturing real estate in its pivot from production specialist to full-time ...

Emergent BioSolutions Inc. and Rocketvax Ltd have announced a strategic partnership involving Emergent's financial investment in Rocketvax's parent company, Swiss Rockets Ltd. This investment will ...

New York State Common Retirement Fund boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) ...